Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 Positive Hospitalized Cancer Patients during the Italian Outbreak: The Cohort Study in Reggio Emilia.
Pinto C, Berselli A, Mangone L, Damato A, Iachetta F, Foracchia M, Zanelli F, Gervasi E, Romagnani A, Prati G, Lui S, Venturelli F, Vicentini M, Besutti G, De Palma R, Giorgi Rossi P. Pinto C, et al. Among authors: zanelli f. Biology (Basel). 2020 Jul 22;9(8):181. doi: 10.3390/biology9080181. Biology (Basel). 2020. PMID: 32707770 Free PMC article.
Mutational Profile of Malignant Pleural Mesothelioma (MPM) in the Phase II RAMES Study.
Pagano M, Ceresoli LG, Zucali PA, Pasello G, Garassino M, Grosso F, Tiseo M, Soto Parra H, Zanelli F, Cappuzzo F, Grossi F, De Marinis F, Pedrazzoli P, Gnoni R, Bonelli C, Torricelli F, Ciarrocchi A, Normanno N, Pinto C. Pagano M, et al. Among authors: zanelli f. Cancers (Basel). 2020 Oct 13;12(10):2948. doi: 10.3390/cancers12102948. Cancers (Basel). 2020. PMID: 33065998 Free PMC article.
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Pinto C, Zucali PA, Pagano M, Grosso F, Pasello G, Garassino MC, Tiseo M, Soto Parra H, Grossi F, Cappuzzo F, de Marinis F, Pedrazzoli P, Bonomi M, Gianoncelli L, Perrino M, Santoro A, Zanelli F, Bonelli C, Maconi A, Frega S, Gervasi E, Boni L, Ceresoli GL. Pinto C, et al. Among authors: zanelli f. Lancet Oncol. 2021 Oct;22(10):1438-1447. doi: 10.1016/S1470-2045(21)00404-6. Epub 2021 Sep 6. Lancet Oncol. 2021. PMID: 34499874 Clinical Trial.
Trabectedin for Patients with Advanced Soft Tissue Sarcoma: A Non-Interventional, Retrospective, Multicenter Study of the Italian Sarcoma Group.
Palmerini E, Sanfilippo R, Grignani G, Buonadonna A, Romanini A, Badalamenti G, Ferraresi V, Vincenzi B, Comandone A, Pizzolorusso A, Brunello A, Gelsomino F, Pas T, Ibrahim T, Grosso F, Zanelli F, Pantaleo MA, Milesi L, Ciuffreda L, Ferrari V, Marchesi E, Quattrini I, Righi A, Setola E, Carretta E, Picci P, Ferrari S. Palmerini E, et al. Among authors: zanelli f. Cancers (Basel). 2021 Mar 2;13(5):1053. doi: 10.3390/cancers13051053. Cancers (Basel). 2021. PMID: 33801399 Free PMC article.
Ifosfamide in non-small cell lung cancer.
Boni C, Zanelli F. Boni C, et al. Among authors: zanelli f. Oncology. 2003;65 Suppl 2:50-4. doi: 10.1159/000073359. Oncology. 2003. PMID: 14586148 Review.
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, Grossi F, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A, Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A; Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Boni C, et al. Among authors: zanelli f. Br J Cancer. 2012 Feb 14;106(4):658-65. doi: 10.1038/bjc.2011.606. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240782 Free PMC article. Clinical Trial.
46 results